France Ultrasound Infertility Diagnosis and Treatment Market Expected to Reach $522.36 Million by 2030-Allied Market Research

According to a new report published by Allied Market Research, titled, " France ultrasound infertility diagnosis and treatment market by Care Pathway and End User: Country Opportunity Analysis and Industry Forecast, 2021–2030," the France ultrasound infertility diagnosis and treatment market was valued at $336.54 million in 2020, and is projected to reach $522.36 million by 2030, growing at a CAGR of 4.4% from 2021 to 2030.

Ultrasound scan is an important aspect of infertility diagnosis and treatment. Ultrasound-guided infertility diagnosis includes numerous procedures that are chosen to identify the infertility issues and assist patients with conception. It uses high-frequency sound waves to create an image of the internal organs. Ultrasound scanning through ultrasound waves is used to detect any reveal details about the ovaries, endometrium, and uterus. Specialized ultrasounds can be performed to assess ovarian reserves, uterine shape, size, and whether the fallopian tubes are open or blocked in greater France ultrasound infertility diagnosis and treatment market detail.

Majority of ultrasounds used for fertility testing and treatment are done transvaginally that is through the vaginal canal with a narrow specialist device. Ultrasounds are minimally invasive, however, can be a little uncomfortable at times. Hysterosonography, hysterosonosalpyngography, ultrasound guided trans-vaginal needle aspiration/biopsy, and core-needle testicular biopsy are various procedures used to identify the cause of infertility.

The factors that drive the growth of the France ultrasound infertility diagnosis and treatment market include rise in infertility rates, increase in trend of delayed pregnancies, technological advancements in ultrasound-guided infertility diagnosis, rise in disposable income, and surge in fertility-related awareness. For instance, in May 2021,

Mindray Medical International Limited, a global leading developer and provider of medical devices and solutions, announced the launch of its new general imaging, women's healthcare, and cardiology ultrasound solutions. Smart Scene 3D, Smart Planes CNS, Smart ICV, Smart Pelvic, and Smart ERA are a few of the expert tools available for women's healthcare ultrasound. These tools especially Smart Pelvic and Smart Scene 3D were designed with a goal of improving efficiency for obstetrics and gynecology (OBGYN) applications such as in vitro fertilization (IVF), neonatal, and postpartum. Thus, such technological advancements are expected to significantly drive the growth of the France ultrasound infertility diagnosis and treatment market.

In addition, rise of infertility rates are not only due to increase in incidence of various diseases but also due to change in lifestyle habit. For instance, increase in physical & psychological stress, rise in alcohol consumption, drug use & medication, environmental & occupational exposure, smoking & tobacco usage are the major factors responsible for decreasing the fertility rate.

Furthermore, the availability and acceptance of IVF technologies and procedures as well as their success rates fuel the demand for frozen embryo transfer procedures, thereby augmenting the France ultrasound infertility diagnosis and treatment market growth.

In addition, increase in prevalence of polycystic ovarian syndrome (PCOS), endometriosis, tubal factors, uterine disorders, and related cancer is anticipated to drive the growth of the France ultrasound infertility diagnosis and treatment market. For instance, according to the International Agency for Research on Cancer and World Health Organization (WHO)’s Globocan 2020 for France, about 10,982 corpus uteri, 3,379 of cervix uteri, 2,752 of testis, and 207 vaginal cancer new cases were recorded. Thus, such cancer cases are further expected to increase infertility cases, leading to increase in demand for diagnosis and treatment monitoring.

However, high cost of infertility diagnostic procedures is expected to hinder the growth of the France ultrasound infertility diagnosis and treatment market. Conversely, initiatives taken by government for development of the technology sector in infertility diagnosis, increase in income level of consumers, rise in number of hospitals, and fertility centers offering diagnosis & treatment monitoring services are anticipated to offer potential growth opportunities for the ultrasound-guided infertility diagnosis & treatment monitoring services market in France.

By care pathway, the France ultrasound infertility diagnosis and treatment market is divided into infertility diagnostics, punction, and treatment monitoring. The treatment monitoring segment generated maximum revenue in 2020, accounting $240.44 million. The infertility diagnostics segment is expected to witness highest CAGR of 6.0% during the forecast period.

Depending on end user, it is divided into public hospital with infertility department, private fertility clinics and ambulatory centers. The private fertility clinics segment dominated the France ultrasound infertility diagnosis and treatment market in 2020 with $223.63 million. The public hospital with infertility department segment is expected to witness highest CAGR of 5.1% during the forecast period.

Key Findings Of The Study

• By care pathway, treatment monitoring was the highest contributor to the France ultrasound infertility diagnosis and treatment market in 2020.
• By end user, private fertility clinics segment exhibited the highest growth in 2020, and is expected to continue this trend during the forecast period.